Literature DB >> 18502405

Dystrophic serotonergic axons in neurodegenerative diseases.

Efrain C Azmitia1, Ralph Nixon.   

Abstract

Neurodegenerative diseases such as Parkinson's disease (PD), frontal lobe dementia (FLD) and diffuse Lewy-body dementia (DLBD) have diverse neuropathologic features. Here we report that serotonin fibers are dystrophic in the brains of individuals with these three diseases. In neuropathologically normal (control) brains (n=3), serotonin axons immunoreactive (IR) with antibodies against the serotonin transporter (5-HTT) protein were widely distributed in cortex (entorhinal and dorsolateral prefrontal), hippocampus and rostral brainstem. 5-HTT-IR fibers-of-passage appeared thick, smooth, and unbranched in medial forebrain bundle, medial lemniscus and cortex white matter. The terminal branches were fine, highly branched and varicose in substantia nigra, hippocampus and cortical gray matter. In the diseased brains, however, 5-HTT-IR fibers in the forebrain were reduced in number and were frequently bulbous, splayed, tightly clustered and enlarged. Morphometric analysis revealed significant differences in the size distribution of the 5-HTT-IR profiles in dorsolateral prefrontal area between neurodegenerative diseases and controls. Our observations provide direct morphologic evidence for degeneration of human serotonergic axons in the brains of patients with neurodegenerative diseases despite the limited size (n=3 slices for each region (3) from each brain (4), total slices was n=36) and the lack of extensive clinical characterization of the analyzed cohort. This is the first report of dystrophic 5-HTT-IR axons in postmortem human tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502405      PMCID: PMC3405553          DOI: 10.1016/j.brainres.2008.03.060

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  61 in total

1.  Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims.

Authors:  M D Underwood; A A Khaibulina; S P Ellis; A Moran; P M Rice; J J Mann; V Arango
Journal:  Biol Psychiatry       Date:  1999-08-15       Impact factor: 13.382

2.  The temporal relationship between depressive symptoms and dementia: a community-based prospective study.

Authors:  P Chen; M Ganguli; B H Mulsant; S T DeKosky
Journal:  Arch Gen Psychiatry       Date:  1999-03

3.  Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease.

Authors:  K Ohara; N Kondo; K Ohara
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1998-02       Impact factor: 5.067

4.  Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals.

Authors:  H W Steinbusch
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

5.  Mechanisms of regrowth in the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. II. Fluorescence histochemical observations.

Authors:  L Wiklund; A Björklund
Journal:  Brain Res       Date:  1980-06-02       Impact factor: 3.252

6.  History of depression and other psychiatric illness as risk factors for Alzheimer disease in a twin sample.

Authors:  J L Wetherell; M Gatz; B Johansson; N L Pedersen
Journal:  Alzheimer Dis Assoc Disord       Date:  1999-01       Impact factor: 2.703

Review 7.  Neurotoxic indoleamines and monoamine neurons.

Authors:  H G Baumgarten; A Björklund
Journal:  Annu Rev Pharmacol Toxicol       Date:  1976       Impact factor: 13.820

Review 8.  Molecular pathways to neurodegeneration.

Authors:  Ella Bossy-Wetzel; Robert Schwarzenbacher; Stuart A Lipton
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

9.  Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites.

Authors:  J Marksteiner; T Walch; T Bodner; P Gurka; E Donnemiller
Journal:  Pharmacopsychiatry       Date:  2003-09       Impact factor: 5.788

10.  The visualization and characterization of 5HT reuptake sites in the rodent and primate hippocampus. A preliminary study.

Authors:  E C Azmitia
Journal:  J Physiol (Paris)       Date:  1981
View more
  21 in total

1.  Age- and duration-dependent effects of MPTP on cortical serotonin systems.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2011-09-21       Impact factor: 3.046

2.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

3.  Brain serotonergic circuitries.

Authors:  Yves Charnay; Lucienne Léger
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

4.  Serotonergic dystrophy induced by excess serotonin.

Authors:  Elizabeth A Daubert; Daniel S Heffron; James W Mandell; Barry G Condron
Journal:  Mol Cell Neurosci       Date:  2010-04-13       Impact factor: 4.314

Review 5.  Serotonin: a regulator of neuronal morphology and circuitry.

Authors:  Elizabeth A Daubert; Barry G Condron
Journal:  Trends Neurosci       Date:  2010-06-18       Impact factor: 13.837

6.  Dystrophic serotonin axons in postmortem brains from young autism patients.

Authors:  Efrain C Azmitia; Jorawer S Singh; Xiao P Hou; Jerzy Wegiel
Journal:  Anat Rec (Hoboken)       Date:  2011-09-08       Impact factor: 2.064

7.  Molecular imaging of serotonin degeneration in mild cognitive impairment.

Authors:  Gwenn S Smith; Frederick S Barrett; Jin Hui Joo; Najlla Nassery; Alena Savonenko; Devin J Sodums; Christopher M Marano; Cynthia A Munro; Jason Brandt; Michael A Kraut; Yun Zhou; Dean F Wong; Clifford I Workman
Journal:  Neurobiol Dis       Date:  2017-05-13       Impact factor: 5.996

8.  Serotonergic modulation of Neural activities in the entorhinal cortex.

Authors:  Saobo Lei
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

9.  Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.

Authors:  Lee A Shapiro; Lynn A Bialowas-McGoey; Patricia M Whitaker-Azmitia
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-22

10.  Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.

Authors:  Tultul Nayyar; Michael Bubser; Marcus C Ferguson; M Diana Neely; J Shawn Goodwin; Thomas J Montine; Ariel Y Deutch; Twum A Ansah
Journal:  Eur J Neurosci       Date:  2009-07       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.